Podcasts

Episode 30 | Treatment Considerations in ALK-Positive NSCLC

Thoracic Oncology Group of Australasia podcast, hosted by: Dr Jenny Lee joined by Professor Nick Pavlakis and Lisa Briggs.

Treatment Considerations in ALK-Positive NSCLC

In this TOGA Podcast, Australian medical oncologist Dr Jenny Lee at Chris O’Brien Lifehouse, Sydney, is joined by medical oncologist Professor Nick Pavlakis, from Royal North Shore Hospital in Sydney and Lisa Briggs, Stage IV lung cancer survivor, Author, Osteopath and Exercise Physiologist who provides her own personal experience after being diagnosed with ALK+ non-small cell lung cancer in 2014.

They discuss treatment of patients with non-small cell lung cancer with ALK mutations, the latest updates on ALK targeted therapies, the emergence of resistance, and how the choice of ALK inhibitor should be made between clinician and patient, taking into account potential side-effects, their management and the impact on the particular patient’s lifestyle.

Play Episode 30 | Treatment Considerations in ALK-Positive NSCLC

More Podcasts

Host A/Prof Prunella Blinman is joined by Prof Nick Pavlakis and Prof Sanjay Popat.
Host A/Prof Steven Kao is joined by A/Prof Venessa Chin and Dr Ben Kong,
Host A/Prof Mel Moore interviews Prof Zarnie Lwin OAM, University of Queensland; Medical Oncologist at Royal Brisbane and Women’s Hospital and The Prince Charles Hospital.
A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer.
Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.
Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.